CYBN:CC News and Press, CYBIN INC. From 11/15/23

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today an...

- Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder - - Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutional shareholders - - Strength...

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to ...

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced a firm commitment underwritten offering of 66,666,667 ...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the...

- CEO Doug Drysdale to speak on panel about innovations in mental health care on November 7, 2023 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new a...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting on interim results from its phase 2 study of CYB003, the company&#x...

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its develop...

- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET - - Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the &#...